Mainz Biomed (NASDAQ:MYNZ) Short Interest Up 190.6% in February

Mainz Biomed (NASDAQ:MYNZ) was the recipient of a large growth in short interest in February. As of February 15th, there was short interest totalling 101,700 shares, a growth of 190.6% from the January 31st total of 35,000 shares. Based on an average daily trading volume, of 203,700 shares, the days-to-cover ratio is presently 0.5 days. Approximately 5.4% of the shares of the stock are sold short.

Mainz Biomed Price Performance

MYNZ opened at $6.04 on Friday. The company’s 50 day simple moving average is $5.38 and its two-hundred day simple moving average is $8.81. The firm has a market capitalization of $12.09 million, a price-to-earnings ratio of -0.09 and a beta of 0.32. Mainz Biomed has a 1-year low of $3.65 and a 1-year high of $45.60.

Hedge Funds Weigh In On Mainz Biomed

An institutional investor recently bought a new position in Mainz Biomed stock. Virtu Financial LLC purchased a new position in shares of Mainz Biomed (NASDAQ:MYNZ) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 18,330 shares of the company’s stock, valued at approximately $79,000. Virtu Financial LLC owned 0.92% of Mainz Biomed as of its most recent SEC filing.

Wall Street Analyst Weigh In

Several equities research analysts have commented on MYNZ shares. HC Wainwright lowered Mainz Biomed from a “buy” rating to a “neutral” rating in a research note on Monday, November 25th. Maxim Group began coverage on shares of Mainz Biomed in a report on Friday, February 14th. They set a “buy” rating and a $14.00 target price for the company.

Mainz Biomed Company Profile

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.